• Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

    来源: Nasdaq GlobeNewswire / 02 4月 2024 07:30:03   America/Chicago

    BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Doug Treco, Ph.D., the company’s chief executive officer and chairman of the board, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 from 10:15-10:55 a.m. ET.

    A live webcast of the fireside chat can be accessed from the Investor Relations section of Inozyme’s website under events, where a replay of the event will also be available for a limited time.

    About Inozyme Pharma

    Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. Inozyme is developing INZ-701, an enzyme replacement therapy, to address pathologic mineralization and intimal proliferation, which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.

    For more information, please visit https://www.inozyme.com/ or follow Inozyme on LinkedInX (formerly Twitter), and Facebook.

    Contacts

    Investors:
    Inozyme Pharma
    Stefan Riley, Senior Director of IR and Corporate Communications
    (857) 330-8871
    stefan.riley@inozyme.com

    Media:
    SmithSolve
    Matt Pera
    (973) 886-9150
    matt.pera@smithsolve.com


    Primary Logo

分享